The painkiller’s marketer will look to partner with another manufacturer to better target primary care physicians, and will also reexamine its sales territories.
Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn’t MannKind set a firm launch date for the product?
The MS pill saw rapid uptake in the US last year, but its overseas launch won’t be as quick, CEO George Scangos conceded this week at an analyst conference.